{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:00:17Z","timestamp":1781175617706,"version":"3.54.1"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T00:00:00Z","timestamp":1709164800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"JSPS KAKENHI","award":["JP22K08079"],"award-info":[{"award-number":["JP22K08079"]}]},{"name":"Clinical Research Promotion Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Streptozocin has been used to treat neuroendocrine tumors in Europe and the USA; however, its actual status in Japan has not been fully clarified owing to the rarity of this disease and the relatively recent approval of streptozocin in Japan.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We retrospectively analyzed 53 patients with gastroenteropancreatic neuroendocrine tumors who were treated with streptozocin-based chemotherapy at two Japanese hospitals between January 2004 and June 2023.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The overall response and disease control rates were 27.7 and 74.5%, respectively, and the median progression-free survival and overall survival were 7.1 and 20.3\u00a0months, respectively. Performance status \u22651 showed a significant negative correlation with progression-free survival, and performance status \u22651 and liver tumor burden \u226525% showed a significant negative correlation with overall survival. No significant differences were observed in the treatment response between pancreatic and gastrointestinal neuroendocrine tumors. No treatment-related serious adverse events were observed; however, 87.7% of patients expressed a decrease in the estimated glomerular filtration rate, which negatively correlated with the duration of streptozocin treatment (r\u00a0=\u00a00.43, P\u00a0=\u00a00.0020). In the streptozocin re-administration group (n\u00a0=\u00a05), no differences were found in efficacy between the initial and second streptozocin treatments.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Although streptozocin is a safe, streptozocin-induced renal dysfunction is a dilemma in streptozocin responders. Streptozocin may benefit patients with gastroenteropancreatic neuroendocrine tumors, especially those with a good performance status; however, in some cases, planned streptozocin withdrawal or switching to other drugs should be considered.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyae026","type":"journal-article","created":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T19:40:15Z","timestamp":1709235615000},"page":"647-657","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of streptozocin-based chemotherapy for gastroenteropancreatic neuroendocrine tumors in Japanese clinical practice"],"prefix":"10.1093","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8791-0052","authenticated-orcid":false,"given":"Masatoshi","family":"Murakami","sequence":"first","affiliation":[{"name":"Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University , Fukuoka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nao","family":"Fujimori","sequence":"additional","affiliation":[{"name":"Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University , Fukuoka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Takamatsu","sequence":"additional","affiliation":[{"name":"Neuroendocrine Tumor Centre, Fukuoka Sanno Hospital , Fukuoka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuhide","family":"Ito","sequence":"additional","affiliation":[{"name":"Neuroendocrine Tumor Centre, Fukuoka Sanno Hospital , Fukuoka , Japan"},{"name":"Department of Gastroenterology , Graduate School of Medical Sciences, , Fukuoka , Japan"},{"name":"International University of Health and Welfare , Graduate School of Medical Sciences, , Fukuoka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhide","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University , Fukuoka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shotaro","family":"Kakehashi","sequence":"additional","affiliation":[{"name":"Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University , Fukuoka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihisa","family":"Ohno","sequence":"additional","affiliation":[{"name":"Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University , Fukuoka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhito","family":"Teramatsu","sequence":"additional","affiliation":[{"name":"Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University , Fukuoka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keijiro","family":"Ueda","sequence":"additional","affiliation":[{"name":"Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University , Fukuoka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kousei","family":"Ishigami","sequence":"additional","affiliation":[{"name":"Department of Clinical Radiology , Graduate School of Medical Sciences, , Fukuoka , Japan"},{"name":"Kyushu University , Graduate School of Medical Sciences, , Fukuoka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University , Fukuoka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,2,29]]},"reference":[{"key":"2024060203004409700_ref1","volume-title":"WHO Classification of Tumours: Digestive System Tumours","author":"Gill","year":"2019","edition":"5th"},{"key":"2024060203004409700_ref2","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1001\/jamaoncol.2022.3395","article-title":"Effectiveness of etoposide and cisplatin vs irinotecan and cisplatin therapy for patients with advanced neuroendocrine carcinoma of the digestive system: the TOPIC-NEC phase 3 randomized clinical trial","volume":"8","author":"Morizane","year":"2022","journal-title":"JAMA Oncol"},{"key":"2024060203004409700_ref3","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1056\/NEJM199202203260804","article-title":"Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma","volume":"326","author":"Moertel","year":"1992","journal-title":"N Engl J Med"},{"key":"2024060203004409700_ref4","doi-asserted-by":"crossref","first-page":"4897","DOI":"10.1200\/JCO.2005.03.616","article-title":"Phase II\/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281","volume":"23","author":"Sun","year":"2005","journal-title":"J Clin Oncol"},{"key":"2024060203004409700_ref5","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1093\/jjco\/hyac048","article-title":"Phase I\/II study of streptozocin monotherapy in Japanese patients with unresectable or metastatic gastroenteropancreatic neuroendocrine tumors","volume":"52","author":"Komoto","year":"2022","journal-title":"Jpn J Clin Oncol"},{"key":"2024060203004409700_ref6","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.pan.2020.06.002","article-title":"Optimal strategy of systemic treatment for unresectable pancreatic neuroendocrine tumors based upon opinion of Japanese experts","volume":"20","author":"Ikeda","year":"2020","journal-title":"Pancreatology"},{"key":"2024060203004409700_ref7","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00535-021-01827-7","article-title":"JNETS clinical practice guidelines for gastroenteropancreatic neuroendocrine neoplasms: diagnosis, treatment, and follow-up: a synopsis","volume":"56","author":"Ito","year":"2021","journal-title":"J Gastroenterol"},{"key":"2024060203004409700_ref8","first-page":"457","article-title":"Nephrotoxicity of streptozotocin (NSC-85998)","volume":"54","author":"Sadoff","year":"1970","journal-title":"Cancer Chemother Rep"},{"key":"2024060203004409700_ref9","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2020.10.014","article-title":"Renal function in patients receiving streptozocin for locally advanced or metastatic digestive neuroendocrine tumours: results of the Streptotox-FFCD 0906 study","volume":"45","author":"Legoux","year":"2021","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"2024060203004409700_ref10","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.ejca.2013.12.011","article-title":"Capecitabine and streptozocin \u00b1 cisplatin in advanced gastroenteropancreatic neuroendocrine tumours","volume":"50","author":"Meyer","year":"2014","journal-title":"Eur J Cancer"},{"key":"2024060203004409700_ref11","doi-asserted-by":"crossref","first-page":"8705","DOI":"10.1038\/s41598-023-35850-w","article-title":"Streptozotocin induces renal proximal tubular injury through p53 signaling activation","volume":"13","author":"Nakai","year":"2023","journal-title":"Sci Rep"},{"key":"2024060203004409700_ref12","doi-asserted-by":"crossref","first-page":"e0143822","DOI":"10.1371\/journal.pone.0143822","article-title":"Streptozocin-based chemotherapy in patients with advanced neuroendocrine neoplasms--predictive and prognostic markers for treatment stratification","volume":"10","author":"Krug","year":"2015","journal-title":"PloS One"},{"key":"2024060203004409700_ref13","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00280-018-3656-y","article-title":"Multi-center clinical evaluation of streptozocin-based chemotherapy for advanced pancreatic neuroendocrine tumors in Japan: focus on weekly regimens and monotherapy","volume":"82","author":"Shibuya","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"2024060203004409700_ref14","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.ejca.2015.04.005","article-title":"Streptozocin\/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours","volume":"51","author":"Dilz","year":"2015","journal-title":"Eur J Cancer"},{"key":"2024060203004409700_ref15","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s12020-021-02859-y","article-title":"Streptozocin\/5-fluorouracil chemotherapy of pancreatic neuroendocrine tumours in the era of targeted therapy","volume":"75","author":"Lahner","year":"2022","journal-title":"Endocrine"},{"key":"2024060203004409700_ref16","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ctrv.2016.01.005","article-title":"Chemotherapy for advanced non-pancreatic well-differentiated neuroendocrine tumours of the gastrointestinal tract, a systematic review and meta-analysis: a lost cause?","volume":"44","author":"Lamarca","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"2024060203004409700_ref17","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s11523-012-0224-y","article-title":"Streptozocin-based chemotherapy is not history in neuroendocrine tumours","volume":"7","author":"Weatherstone","year":"2012","journal-title":"Target Oncol"},{"key":"2024060203004409700_ref18","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/bjc.2014.660","article-title":"O6-Methylguanine-DNA methyltransferase status in neuroendocrine tumours: prognostic relevance and association with response to alkylating agents","volume":"112","author":"Walter","year":"2015","journal-title":"Br J Cancer"},{"key":"2024060203004409700_ref19","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00280-018-3700-y","article-title":"Clinical and in vitro studies of the correlation between MGMT and the effect of streptozocin in pancreatic NET","volume":"83","author":"Hijioka","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"key":"2024060203004409700_ref20","doi-asserted-by":"crossref","first-page":"7535","DOI":"10.1038\/s41598-023-34666-y","article-title":"MGMT is frequently inactivated in pancreatic NET-G2 and is associated with the therapeutic activity of STZ-based regimens","volume":"13","author":"Yagi","year":"2023","journal-title":"Sci Rep"},{"key":"2024060203004409700_ref21","doi-asserted-by":"crossref","first-page":"839","DOI":"10.6004\/jnccn.2021.0032","article-title":"Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Shah","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"2024060203004409700_ref22","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","article-title":"Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Pavel","year":"2020","journal-title":"Ann Oncol"},{"key":"2024060203004409700_ref23","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s00535-014-1006-3","article-title":"Streptozocin chemotherapy for advanced\/metastatic well-differentiated neuroendocrine tumors: an analysis of a multi-center survey in Japan","volume":"50","author":"Aoki","year":"2015","journal-title":"J Gastroenterol"},{"key":"2024060203004409700_ref24","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/1097-0142(197410)34:4<993::AID-CNCR2820340404>3.0.CO;2-T","article-title":"Clinical antitumor activity and toxicity of streptozotocin (NSC-85998)","volume":"34","author":"Schein","year":"1974","journal-title":"Cancer"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/54\/6\/647\/58038855\/hyae026.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/54\/6\/647\/58038855\/hyae026.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T03:01:02Z","timestamp":1717297262000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/54\/6\/647\/7616409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,29]]},"references-count":24,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,2,29]]},"published-print":{"date-parts":[[2024,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyae026","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6]]},"published":{"date-parts":[[2024,2,29]]}}}